Table 3. Open in new tab SF-36 Scores at...

SF-36 Domain	Placebo (n=39)	rhPTH(1-84) (n=83)	rhPTH(1-84) vs Placebo
PF	45.4 (1.5)	46.8 (1.7)	1.3 (1.2)	0.278	49.2 (1.0)	50.1 (1.1)	1.4 (0.8)	0.071	0.894
RP	46.3 (1.6)	47.0 (1.6)	−0.9 (1.3)	0.476	47.8 (1.0)	49.7 (1.0)	1.2 (0.9)	0.167	0.143
BP	48.1 (1.4)	47.9 (1.7)	−0.6 (1.4)	0.662	48.3 (1.2)	50.8 (1.3)	2.0 (1.0)	0.042	0.106
GH	46.3 (2.0)	46.6 (2.1)	−0.2 (1.1)	0.843	46.1 (1.3)	48.5 (1.2)	2.0 (0.8)	0.016	0.088
VT	47.7 (1.8)	50.0 (1.9)	1.6 (1.4)	0.258	49.5 (1.3)	53.0 (1.1)	3.7 (1.0)	<0.001	0.173
SF	48.1 (1.6)	48.5 (1.7)	−0.6 (1.4)	0.677	48.8 (1.2)	50.0 (1.1)	0.4 (1.0)	0.695	0.541
RE	47.1 (1.8)	49.0 (1.6)	−0.2 (1.3)	0.885	49.5 (1.1)	49.9 (1.0)	−0.6 (0.9)	0.528	0.795
MH	48.8 (1.9)	50.0 (2.0)	−0.3 (1.2)	0.807	50.8 (1.2)	52.8 (1.1)	1.2 (0.9)	0.175	0.283
PCS	46.0 (1.3)	46.3 (1.6)	−0.1 (1.0)	0.961	47.3 (1.1)	49.3 (1.0)	2.0 (0.7)	0.004	0.074
MCS	48.9 (1.9)	50.5 (1.9)	0.2 (1.2)	0.892	50.4 (1.2)	51.9 (1.1)	0.7 (0.8)	0.427	0.704

SF-36 Domain

Placebo (n=39)

rhPTH(1-84) (n=83)

rhPTH(1-84) vs Placebo

Baseline

Week 24

LS Mean Change (SE)^a

P Value^b

Baseline

Week 24

LS Mean Change (SE)^a

P Value^b

P Value^c

45.4 (1.5)

46.8 (1.7)

1.3 (1.2)

0.278

49.2 (1.0)

50.1 (1.1)

1.4 (0.8)

0.071

0.894

46.3 (1.6)

47.0 (1.6)

−0.9 (1.3)

0.476

47.8 (1.0)

49.7 (1.0)

1.2 (0.9)

0.167

0.143

48.1 (1.4)

47.9 (1.7)

−0.6 (1.4)

0.662

48.3 (1.2)

50.8 (1.3)

2.0 (1.0)

0.042

0.106

46.3 (2.0)

46.6 (2.1)

−0.2 (1.1)

0.843

46.1 (1.3)

48.5 (1.2)

2.0 (0.8)

0.016

0.088

47.7 (1.8)

50.0 (1.9)

1.6 (1.4)

0.258

49.5 (1.3)

53.0 (1.1)

3.7 (1.0)

<0.001

0.173

48.1 (1.6)

48.5 (1.7)

−0.6 (1.4)

0.677

48.8 (1.2)

50.0 (1.1)

0.4 (1.0)

0.695

0.541

47.1 (1.8)

49.0 (1.6)

−0.2 (1.3)

0.885

49.5 (1.1)

49.9 (1.0)

−0.6 (0.9)

0.528

0.795

48.8 (1.9)

50.0 (2.0)

−0.3 (1.2)

0.807

50.8 (1.2)

52.8 (1.1)

1.2 (0.9)

0.175

0.283

PCS

46.0 (1.3)

46.3 (1.6)

−0.1 (1.0)

0.961

47.3 (1.1)

49.3 (1.0)

2.0 (0.7)

0.004

0.074

MCS

48.9 (1.9)

50.5 (1.9)

0.2 (1.2)

0.892

50.4 (1.2)

51.9 (1.1)

0.7 (0.8)

0.427

0.704

SF-36 Domain	Placebo (n=39)	rhPTH(1-84) (n=83)	rhPTH(1-84) vs Placebo
PF	45.4 (1.5)	46.8 (1.7)	1.3 (1.2)	0.278	49.2 (1.0)	50.1 (1.1)	1.4 (0.8)	0.071	0.894
RP	46.3 (1.6)	47.0 (1.6)	−0.9 (1.3)	0.476	47.8 (1.0)	49.7 (1.0)	1.2 (0.9)	0.167	0.143
BP	48.1 (1.4)	47.9 (1.7)	−0.6 (1.4)	0.662	48.3 (1.2)	50.8 (1.3)	2.0 (1.0)	0.042	0.106
GH	46.3 (2.0)	46.6 (2.1)	−0.2 (1.1)	0.843	46.1 (1.3)	48.5 (1.2)	2.0 (0.8)	0.016	0.088
VT	47.7 (1.8)	50.0 (1.9)	1.6 (1.4)	0.258	49.5 (1.3)	53.0 (1.1)	3.7 (1.0)	<0.001	0.173
SF	48.1 (1.6)	48.5 (1.7)	−0.6 (1.4)	0.677	48.8 (1.2)	50.0 (1.1)	0.4 (1.0)	0.695	0.541
RE	47.1 (1.8)	49.0 (1.6)	−0.2 (1.3)	0.885	49.5 (1.1)	49.9 (1.0)	−0.6 (0.9)	0.528	0.795
MH	48.8 (1.9)	50.0 (2.0)	−0.3 (1.2)	0.807	50.8 (1.2)	52.8 (1.1)	1.2 (0.9)	0.175	0.283
PCS	46.0 (1.3)	46.3 (1.6)	−0.1 (1.0)	0.961	47.3 (1.1)	49.3 (1.0)	2.0 (0.7)	0.004	0.074
MCS	48.9 (1.9)	50.5 (1.9)	0.2 (1.2)	0.892	50.4 (1.2)	51.9 (1.1)	0.7 (0.8)	0.427	0.704

Table 3.

Open in new tab

SF-36 Scores at Baseline and After 24 Weeks of Treatment

SF-36 Domain	Placebo (n=39)				rhPTH(1-84) (n=83)				rhPTH(1-84) vs Placebo
SF-36 Domain	Baseline	Week 24	LS Mean Change (SE)^a	P Value^b	Baseline	Week 24	LS Mean Change (SE)^a	P Value^b	P Value^c
PF	45.4 (1.5)	46.8 (1.7)	1.3 (1.2)	0.278	49.2 (1.0)	50.1 (1.1)	1.4 (0.8)	0.071	0.894
RP	46.3 (1.6)	47.0 (1.6)	−0.9 (1.3)	0.476	47.8 (1.0)	49.7 (1.0)	1.2 (0.9)	0.167	0.143
BP	48.1 (1.4)	47.9 (1.7)	−0.6 (1.4)	0.662	48.3 (1.2)	50.8 (1.3)	2.0 (1.0)	0.042	0.106
GH	46.3 (2.0)	46.6 (2.1)	−0.2 (1.1)	0.843	46.1 (1.3)	48.5 (1.2)	2.0 (0.8)	0.016	0.088
VT	47.7 (1.8)	50.0 (1.9)	1.6 (1.4)	0.258	49.5 (1.3)	53.0 (1.1)	3.7 (1.0)	<0.001	0.173
SF	48.1 (1.6)	48.5 (1.7)	−0.6 (1.4)	0.677	48.8 (1.2)	50.0 (1.1)	0.4 (1.0)	0.695	0.541
RE	47.1 (1.8)	49.0 (1.6)	−0.2 (1.3)	0.885	49.5 (1.1)	49.9 (1.0)	−0.6 (0.9)	0.528	0.795
MH	48.8 (1.9)	50.0 (2.0)	−0.3 (1.2)	0.807	50.8 (1.2)	52.8 (1.1)	1.2 (0.9)	0.175	0.283
PCS	46.0 (1.3)	46.3 (1.6)	−0.1 (1.0)	0.961	47.3 (1.1)	49.3 (1.0)	2.0 (0.7)	0.004	0.074
MCS	48.9 (1.9)	50.5 (1.9)	0.2 (1.2)	0.892	50.4 (1.2)	51.9 (1.1)	0.7 (0.8)	0.427	0.704

SF-36 Domain	Placebo (n=39)				rhPTH(1-84) (n=83)				rhPTH(1-84) vs Placebo
SF-36 Domain	Baseline	Week 24	LS Mean Change (SE)^a	P Value^b	Baseline	Week 24	LS Mean Change (SE)^a	P Value^b	P Value^c
PF	45.4 (1.5)	46.8 (1.7)	1.3 (1.2)	0.278	49.2 (1.0)	50.1 (1.1)	1.4 (0.8)	0.071	0.894
RP	46.3 (1.6)	47.0 (1.6)	−0.9 (1.3)	0.476	47.8 (1.0)	49.7 (1.0)	1.2 (0.9)	0.167	0.143
BP	48.1 (1.4)	47.9 (1.7)	−0.6 (1.4)	0.662	48.3 (1.2)	50.8 (1.3)	2.0 (1.0)	0.042	0.106
GH	46.3 (2.0)	46.6 (2.1)	−0.2 (1.1)	0.843	46.1 (1.3)	48.5 (1.2)	2.0 (0.8)	0.016	0.088
VT	47.7 (1.8)	50.0 (1.9)	1.6 (1.4)	0.258	49.5 (1.3)	53.0 (1.1)	3.7 (1.0)	<0.001	0.173
SF	48.1 (1.6)	48.5 (1.7)	−0.6 (1.4)	0.677	48.8 (1.2)	50.0 (1.1)	0.4 (1.0)	0.695	0.541
RE	47.1 (1.8)	49.0 (1.6)	−0.2 (1.3)	0.885	49.5 (1.1)	49.9 (1.0)	−0.6 (0.9)	0.528	0.795
MH	48.8 (1.9)	50.0 (2.0)	−0.3 (1.2)	0.807	50.8 (1.2)	52.8 (1.1)	1.2 (0.9)	0.175	0.283
PCS	46.0 (1.3)	46.3 (1.6)	−0.1 (1.0)	0.961	47.3 (1.1)	49.3 (1.0)	2.0 (0.7)	0.004	0.074
MCS	48.9 (1.9)	50.5 (1.9)	0.2 (1.2)	0.892	50.4 (1.2)	51.9 (1.1)	0.7 (0.8)	0.427	0.704

Data given as unadjusted mean (SE) unless otherwise indicated. The analysis used an MMRM. The analyses included the fixed, categorical effects of rhPTH(1-84), treatment, region, sex, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of age, baseline HRQoL score, and the baseline-by-visit interaction. An unstructured covariance structure shared across treatment groups was used to model the within-patient errors. For all domains, normal population has the mean of 50 and a standard deviation of 10.

Abbreviation: RE, role-emotional.

LS mean change is the model-based mean change from baseline to week 24.

Within-treatment–group P value.

Between-treatment–group P value.

This Feature Is Available To Subscribers Only